Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Menée in vitro et à l'aide de modèles murins de différents types de tumeurs (vessie, sein, mélanome, côlon, prostate), cette étude met en évidence un mécanisme par lequel le transporteur de sérotonine supprime l'immunité antitumorale en inhibant la réactivité des lymphocytes T CD8+ via la déplétion de la sérotonine sécrétée dans le microenvironnement
Identifying additional immune checkpoints hindering antitumor T cell responses is key to the development of next-generation cancer immunotherapies. Here, we report the induction of serotonin transporter (SERT), a regulator of serotonin levels and physiological functions in the brain and peripheral tissues, in tumor-infiltrating CD8 T cells. Inhibition of SERT using selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed antidepressants, significantly suppressed tumor growth and enhanced T cell antitumor immunity in various mouse syngeneic and human xenograft tumor models. Importantly, SSRI treatment exhibited significant therapeutic synergy with programmed cell death protein 1 (PD-1) blockade, and clinical data correlation studies negatively associated intratumoral SERT expression with patient survival in a range of cancers. Mechanistically, SERT functions as a negative-feedback regulator inhibiting CD8 T cell reactivities by depleting intratumoral T cell-autocrine serotonin. These findings highlight the significance of the intratumoral serotonin axis and identify SERT as an immune checkpoint, positioning SSRIs as promising candidates for cancer immunotherapy.
Cell , article en libre accès, 2025